Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kensuke Oikawa

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Journal of Translational Medicine|June 22, 2019
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinomaYui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, et al.
Cancer Science|January 27, 2024
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinomaToshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, et al.
The Journal of Experimental Medicine|September 24, 2021
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytesAkemi Kosaka, Kei Ishibashi, Toshihiro Nagato, et al.
Molecular and Cellular Neurosciences|January 3, 2015
Early growth response 2 (Egr-2) expression is triggered by NF-κB activationSolmaz Nafez, Kensuke Oikawa, Gary L Odero, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2017
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapyToshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2023
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapyToshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, et al.
Oncoimmunology|January 18, 2021
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinomaRyusuke Hayashi, Toshihiro Nagato, Takumi Kumai, et al.
Cancer Science|May 19, 2021
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapyAkemi Kosaka, Yuki Yajima, Mayumi Hatayama, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of Translational Medicine|June 22, 2019
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinomaYui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, et al.
Cancer Science|January 27, 2024
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinomaToshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, et al.
The Journal of Experimental Medicine|September 24, 2021
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytesAkemi Kosaka, Kei Ishibashi, Toshihiro Nagato, et al.
Molecular and Cellular Neurosciences|January 3, 2015
Early growth response 2 (Egr-2) expression is triggered by NF-κB activationSolmaz Nafez, Kensuke Oikawa, Gary L Odero, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2017
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapyToshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2023
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapyToshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, et al.
Oncoimmunology|January 18, 2021
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinomaRyusuke Hayashi, Toshihiro Nagato, Takumi Kumai, et al.
Cancer Science|May 19, 2021
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapyAkemi Kosaka, Yuki Yajima, Mayumi Hatayama, et al.
Pageof 6